Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors
✍ Scribed by Christine Meffre; Yann Le Strat; Elisabeth Delarocque-Astagneau; Fréderic Dubois; Denise Antona; Jean-Marie Lemasson; Josiane Warszawski; Josiane Steinmetz; Dominique Coste; Jean-François Meyer; Sandrine Leiser; Jean-Pierre Giordanella; René Gueguen; Jean-Claude Desenclos
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 123 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
To monitor the prevalence of hepatitis B and hepatitis C a cross‐sectional survey was conducted in 2004 among French metropolitan residents. A complex sampling design was used to enroll 14,416 adult participants aged 18–80 years. Data collected included demographic and social characteristics and risk factors. Sera were tested for anti‐HCV, HCV‐RNA, anti‐HBc and HBsAg. Data were analyzed with SUDAAN® software to provide weighted estimates for the French metropolitan resident population. The overall anti‐HCV prevalence was 0.84% (95% CI: 0.65–1.10). Among anti‐HCV positive individuals, 57.4% (95% CI: 43.2–70.5) knew their status. Factors associated independently with positive anti‐HCV were drug use (intravenous and nasal), blood transfusion before 1992, a history of tattoos, low socioeconomic status, being born in a country where anti‐HCV prevalence >2.5%, and age >29 years. The overall anti‐HBc prevalence was 7.3% (95%: 6.5–8.2). Independent risk factors for anti‐HBc were intravenous drug use, being a man who has sex with men, low socioeconomic status, a stay in a psychiatric facility or facility for the mentally disabled, <12 years of education, being born in a country where HBsAg prevalence >2%, age >29 and male sex. The HCV RNA and HBsAg prevalence were 0.53% (95% CI: 0.40–0.70) and 0.65% (95% CI: 0.45–0.93), respectively. Among HBsAg positive individuals, 44.8% (95% CI: 22.8–69.1) knew their status. Anti‐HCV prevalence was close to the 1990s estimates whereas HBsAg prevalence estimate was greater than expected. Screening of hepatitis B and C should be strengthened and should account for social vulnerability. J. Med. Virol. 82:546–555, 2010. © 2010 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Background: Data regarding the prevalence of hepatitis c (hcv) and hepatitis b (hbv) in inflammatory bowel disease (ibd) patients are conflicting. ## Methods: In all, 315 ibd (252 crohn's disease [cd] and 63 ulcerative colitis [uc]) patients were consecutively recruited between june 2005 and m